Elena Giudice

Gyn Onco Clinician at Fondazione Policlinico Universitario A.Gemelli IRCCS,Rome,Italy |Former PostDoctoral Fellow at @NCICCR_WMB NIH/NCI, Bethesda, MD, U.S.

[Elena Giudice @EleGiudiceMD]

Such a humbling and unforgettable experience to present my poster surrounded by #gyncsm giants at #ASCO23 ♥️ dreams come true when someone believes in you.
#OvarianCancer #research @NCICCR_WMB @theNCI @NCIResearchCtr

[Giovanni Maria Iannantuono @GMIannantuonoMD]

❓Are cancer CTs only for patients with good PS?

🔹Only 25.8% of 283 pivotal CTs included ECOG PS ≥2 pts.
🔸 Median enrollment was 4.3%

💡Real change needs Sponsors, IRBs/ECs, Investigators working together

👉🏻Read the full paper: https://t.co/p5Kj0bD5cY

[Giovanni Maria Iannantuono @GMIannantuonoMD]

I am deeply grateful to my co-authors from Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome 🇮🇹)
@SSgangaMD @TommasoGiovagnoli @EleGiudiceMD @RRosenfeld @antoniovitaleMD @marcof @PLombardi @EBria @PTroisi @ERapisarda

[ESGO @ESGO_society]

The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence to and personal friend of many of our members. A moment of silence was held today during the Congress opening ceremony in his honour.

Prof Scambia touched the lives of countless patients, surgeons, fellows and others in the gynae oncology community.

We extend our condolences to his family and the many, many others who are mourning his passing. His memory will live on.

[Giovanni Maria Iannantuono @GMIannantuonoMD]

Lights and shadows of tumor-agnostic cancer therapies 💡🔎
A great lecture at #AIOM24 by an expert clinical trialist like @Gen_Daniele 💥

[C. 'Harris' Floudas @chfloudas]

Some kids with Cushing hypercortisolism are not obese. Curious if that's biological/behavioral/combination.
https://t.co/JCPbw7t7ZA

[Giovanni Maria Iannantuono @GMIannantuonoMD]

Huge congrats to @apolo_andrea, an incredible physician-scientist and a true leader dedicated to improve the life of bladder cancer patients 🥇

#ESMO24 @myESMO

@nciccr_gmb @NCICCR_MOS @NCIResearchCtr @theNCI

[Elena Giudice @EleGiudiceMD]

So proud to see the final OS data of KEYNOTE-A18 study in the #ESMO24 Presidential Symposium #practicechangingtrials presented by my Mentor @ketta_lorusso ♥️. We can say today to #cervicalcancer patients: we have worked very hard but now this is reality. #fightingcancer

[AIOM @AIOMtweet]

Un successo il Congresso Nazionale di AIOM Giovani 2024. Un grande lavoro del Working Group giovani.
#AIOM #CongressoNazionaleAIOMgiovani

[ESMO - Eur. Oncology @myESMO]

#ESMOGynae24: Advances over the last decade have significantly transformed the management of #GynaecologicalCancers, particularly the prevention and treatment of three main types: endometrial, cervical, and ovarian cancer. #ESMODailyReporter
📌https://t.co/yukQ1fRnmt

[OncoDaily @oncodaily]

🚨New Paper Alert! 🚨Understanding MSI and MMR in Urothelial Carcinoma: Systematic Review and Meta-analysis
@BMJOncology @NIH @SaadAtiq24 @NicholasISimon @RoufDr @eliaschandran @GMIannantuonoMD @SandeepGurramMD @DrRosenbergMSK

Summary by @amalsargsyan
https://t.co/xpZaXezeg7

[BMJ Oncology @BMJOncology]

A study in BMJ Oncology suggests MMR-D/MSI-H urothelial cancer may confer high sensitivity to immunotherapy. This could spare patients the morbidity of radical surgery and the toxicities of chemotherapy.

@apolo_andrea @EliasChandran @GMIannantuonoMD

https://t.co/UXkRysD483

[Andrea Apolo, M.D. @apolo_andrea]

Great #BCAN @BladderCancerUS walk today in the DC with family, 🐕, friends, colleagues, and patients. #NoOneWalksAlone #BladderCancer #UrothelialCarcinoma
#BladderCancerResearch Team
@DrAndreKydd @SaadAtiq24 @EliasChandran @prokuninaolsson @RoufDr @PChoyke @GUMDROPtrials

[Elena Giudice @EleGiudiceMD]

Very honoured to have had the opportunity to work on this project at the @NCIResearchCtr with such a great mentor and PI, Dr. Jung-Min Lee, and all the members of her lab ♥️ #ovariancancer needs #research 👩‍🔬🔬🧪

[The Oncologist @OncJournal]

#ChatGPT-4 & ChatGPT-3.5 are potentially powerful tools in #immunooncology, but risk of inaccurate/incomplete responses stresses the importance of expert-driven verification of outputs generated by these #AI technologies. @chfloudas @GMIannantuonoMD https://t.co/fnH9xlmRea

[C. 'Harris' Floudas @chfloudas]

So #LLMs can pass the USMLE, how about specialist knowledge, such as our own field of #Oncology #Immunotherapy? @GMIannantuonoMD and a team of colleagues @DBrackenClarke @FatimaKarzai @gulleyj1 set out to explore this question.
https://t.co/4jZAdd7Fsi

[OncLive.com @OncLive]

.@US_FDA Grants Priority Review to Tisotumab Vedotin sBLA for Recurrent or Metastatic Cervical Cancer #gyncsm https://t.co/SNXfTKCOiK

[Elena Giudice @EleGiudiceMD]

What a great day for #cervicalcancer patients. Thanks to the practice-changing trial #KEYNOTEA18 presented by Prof @ketta_lorusso at #ESMO23, #immunotherapy is now available in combination with RTCT for the locally advanced setting. ♥️ #FDA #approval #gynonc #pembrolizumab

[OncLive.com @OncLive]

BREAKING: @US_FDA Approves Pembrolizumab Plus Chemoradiation for FIGO 2014 Stage III to IVA Cervical Cancer #gyncsm https://t.co/sWBKyg6Baz

[Giovanni Maria Iannantuono @GMIannantuonoMD]

🔍Do Italian clinical trials report the race and ethnicity of the enrolled population?
⁦#AIOM23 @AIOMtweet⁩
⁦@unitorvergata⁩

Thanks to a special friend like ⁦@SSgangaMD⁩ for his valuable contribution 💪🏻

[Elena Giudice @EleGiudiceMD]

Atezo bev and platinum based chemo regardless of PD-L1 status. Every #cervicalcancer patient deserves #ICIs. Congratulations to @AnaOaknin for those outstanding results! #BEATcc trial #esmo #plenary #gynonc

[@gulleyj1 @gulleyj1]

#SITC23 TME with cold areas, hypoxia areas, and lush meadows of growth. Great analogy. #keynote